Novo Nordisk Raises 2026 Outlook As Adjusted Operating Profit Climbs 27% On Wegovy Pill Sales
Reported operating profit fell 9% on DKK 8.7 billion of non-cash impairments, and CFO Karsten Munk Knudsen will leave at the end of December.
Novo Nordisk, the Danish maker of Ozempic and Wegovy, raised its 2026 outlook on Wednesday after third-quarter adjusted operating profit rose 27% at constant exchange rates to DKK 31,720 million. Part of the jump comes from an easy comparison: the year-earlier quarter carried about DKK 9 billion of company-wide transformation costs.
Obesity drugs carry the quarter
Adjusted and reported sales both rose 4% at constant exchange rates to DKK 79,195 million, driven by GLP-1 volume growth, mainly in obesity, the company said. Total obesity sales climbed 22% to DKK 26,146 million.
The Wegovy pill, launched in the US on 5 January, brought in DKK 5,394 million in the quarter, of which DKK 4,178 million came from US Operations. It had reached four markets by the end of the quarter and eight since. Diabetes sales fell 5% at constant rates to DKK 47,545 million.
CEO Mike Doustdar said Novo delivered a "stronger-than-expected third quarter" and is preparing for a US launch of CagriSema in early 2027, subject to regulatory approval.
Impairments hit reported profit
Reported operating profit moved the other way, falling 9% at constant rates to DKK 23,011 million. The drag was DKK 8.7 billion of non-cash impairments: DKK 4.6 billion tied to ziltivekimab and DKK 4.1 billion for right-sizing the manufacturing network. Net profit fell 16% to DKK 16,740 million.
Novo is a Denmark-based company selling drugs for obesity, diabetes and rare diseases. The ziltivekimab charge follows phase 3 trials that did not meet their main goal.
A guidance lift, and a new CFO
Adjusted sales growth for 2026 is now expected at -2% to +2% at constant rates, up from -6% to 0% on 4 August. Adjusted operating profit growth gets the same range. Free cash flow is now guided to DKK 60 to 70 billion, from DKK 45 to 55 billion.
The outlook still assumes lower US realised prices, including the Most Favoured Nations agreement, and pressure from semaglutide losing exclusivity in certain international markets.
CFO Karsten Munk Knudsen and Novo mutually agreed he will leave, and he stays until the end of December 2026. Luigi La Corte, currently CFO of Galderma, will succeed him.
Novo's US-listed shares closed at $40.19 on Tuesday, before the report, for a market value of $177.3 billion.
Novo expects an FDA decision on the 25 mg Ozempic pill in the fourth quarter, and its full-year 2026 report is due 3 February 2027.